This CME-accredited activity, Best of Hematology and Breast Cancer II, is designed to offer practical insights into hematology and breast cancer care by educating clinicians involved in cancer care. This activity is designed to provide physicians, physician assistants, nurse practitioners, pharmacists, nurses, and other healthcare professionals with the latest updates in the field. It will highlight a multidisciplinary approach and the integration of new advances in patient-centered care of breast cancer.
Course Accreditations
Course Summary
| Events Starts | Events Ends |
|---|---|
| 1/1/2025 | 12/31/2025 |
Faculty
Shipra Gandhi (MD)
Dr. Shipra Gandhi is an Associate Professor of Oncology at Roswell Park Comprehensive Cancer center, specializing in treating patients with breast cancer. She completed her internal medicine residency at University at Buffalo, followed by hematology-oncology fellowship at Roswell Park Comprehensive Cancer Center. Her clinical interests are in breast cancer. Her research interests include biomarkers for response and toxicities, novel therapeutics for triple negative breast cancer and clinical outcomes by racial disparities.
Disclosure
Financial relationships Yes, I have had a financial relationship with an ineligible company within the past 24 months. Financial relationships: Attribution: Self Type of financial relationship: Other Ineligible company: Astrazeneca Topic: T-DXD Relationship end date: 07/15/2022 Attribution: Self Type of financial relationship: Other Ineligible company: Novartis Topic: Ribociclib Relationship end date: 11/27/2023 Type of financial relationship: Professional Services Ineligible company: OncLive Type of financial relationship: Professional Services Ineligible company: MedPage Today Type of financial relationship: Professional Services Ineligible company: Aptitude Health
Nora Bucher (MD)
Dr. Bucher is a board-certified medical oncologist and hematologist. In addition to over 15 years of clinical experience, Dr. Bucher has subspecialty training and breast cancer, cancer genetics and genomics, and pharmacology. She has also contributed extensively to breast cancer research. She treats all types of cancer, but does have special interest in breast cancer, central nervous system malignancies, lung cancer, melanoma, and blood cancers. She also enjoys diagnosing and managing various benign hematologic disorders. She is renowned for her compassionate bedside manner and easygoing sense of humor. When not working, Dr. Bucher loves to travel, cook, watch goofy movies, and spend time with her husband, two children, and two dogs.
Disclosure
Financial relationships Yes, I have had a financial relationship with an ineligible company within the past 24 months.
Joshua Gruber (MD, PhD)
Joshua Gruber, M.D., Ph.D., is an Assistant Professor in the Department of Internal Medicine at UT Southwestern Medical Center. A breast cancer specialist, he has a secondary appointment in UTSW’s Cecil H. and Ida Green Center for Reproductive Biology Sciences. Dr. Gruber earned his medical degree and doctoral degree in cancer biology and biochemistry at the University of Pennsylvania. He completed a residency in internal medicine at Stanford University, where he also received advanced training through a clinical fellowship in medical oncology and a research fellowship in systems biology of cancer epigenetics. Certified by the American Board of Internal Medicine in medical oncology, he joined the UT Southwestern faculty in 2021. Dr. Gruber is the author of numerous scholarly articles in journals such as Cell, Molecular Cell, and Cell Reports, and he serves as a peer reviewer for the Journal of Clinical Oncology Precision Oncology, Clinical Cancer Research, Nature Cancer and Nature Medicine. His clinical focus is on treating patients with metastatic breast cancer and triple-negative breast cancer, as well as conducting early-stage clinical trials on new therapies for these diseases. His laboratory research interests include the molecular biology of breast cancer initiation, the intersection of tumor immunology with cancer growth pathways, and the development of molecular tools to interrogate neoplastic tissues. He is also focused on gene regulation, specifically the intersection of cancer epigenetics with cellular metabolism. In particular, his work is directed at devising new methods for understanding how metabolic products affect chromatin landscapes as well as developing new chemical probes to interrogate this process. Dr. Gruber is a member of the American Association for Cancer Research, the American Society of Clinical Oncology, and the Society for Immunotherapy of Cancer.
Disclosure
Financial relationships Yes, I have had a financial relationship with an ineligible company within the past 24 months. Financial relationships: Attribution: Spouse or Partner Type of financial relationship: Employment Ineligible company: Guardant Health Topic: ctDNA Attribution: Self Type of financial relationship: Grant Or Contract Ineligible company: Hummingbird Bioscience Topic: Cancer Therapeutics Attribution: Self Type of financial relationship: Independent contractor Ineligible company: Guidepoint Topic: Oncology Attribution: Self Type of financial relationship: Independent contractor Ineligible company: Sharma Therapeutics Topic: Oncology Attribution: Self Type of financial relationship: Independent contractor Ineligible company: Hologic Topic: Diagnostics Breast Cancer Relationship end date: 12/09/
Amit Garg (MD)
Dr. Garg serves as Medical Director of Radiation Oncology at Presbyterian Healthcare Services as well as Medical Director of Quality for the Cancer Program. He graduated from Baylor College of Medicine and also earned an MA in Biomedical Ethics from Case Western Reserve University School of Medicine. He completed a residency in Radiation Oncology at MD Anderson Cancer Center and was on the faculty at MD Anderson for 13 years prior to joining PHS. He is a published author on a variety of cancer-related topics including breast cancer, prostate cancer, and stereotactic radiotherapy for tumors in the spine, brain and elsewhere.
Disclosure
Financial relationships No, I have not had a financial relationship with an ineligible company within the past 24 months.
Mark Pegram (MD)
Mark Pegram, MD, is the Suzy Yuan-Huey Hung Endowed Professor of Medical Oncology at the Stanford University School of Medicine. He currently serves as the Associate Director of Clinical Research at the Stanford Comprehensive Cancer Institute (SCCI). Dr. Pegram also serves as the Associate Dean for Clinical Research Quality at the Stanford University School of Medicine, and is the Medical Director of the Stanford Clinical Translational Research Unit. Dr. Pegram is the recipient of BTF Eternal Service award for his dedication to educating doctors, and improving the lives of cancer patients through his breakthrough research and clinical care.
Disclosure
Financial relationships Yes, I have had a financial relationship with an ineligible company within the past 24 months. Financial relationships: Attribution: Self Type of financial relationship: Other Ineligible company: Novartis Topic: Consultant Relationship end date: 12/31/2024 Attribution: Self Type of financial relationship: Other Ineligible company: Gilead Topic: Consultant Relationship end date: 12/31/2024 Attribution: Self Type of financial relationship: Other Ineligible company: Roche/Genentech Topic: Consultant Relationship end date: 12/31/2024 Attribution: Self Type of financial relationship: Other Ineligible company: Astra-Zeneca/Daiichi Sankyo Topic: Consultant Relationship end date: 12/31/2024
Bernard Tawfik (MD)
Bernard Tawfik MD, is Assistant Professor in Department of Internal Medicine, Division of Hematology Oncology and a board certified, practicing medical oncologist at the University of New Mexico Cancer Comprehensive Center (UNM CCC). His clinical interest lies in the treatment of solid tumors with a focus on breast cancer and neuroendocrine tumors. His research has focused on the cancer care delivery, quality improvement and health disparities research. He is actively involved in the conduct of clinical trials, is involved in the Breast Cancer Working Group Protocol Development Committee at UNM CCC, and sits on the Data Safety Monitoring Committee for the UNM CCC. He has cultivated collaboration with UNM Behavioral Measurement and Population Sciences and the New Mexico Department of Health. These collaborations have resulted in an investigator initiated clinical protocol evaluating the use of Patient Reported Outcomes (PRO) to assess patient, staff and provider views and patient understanding of adjuvant endocrine therapy. He has further collaborations and publications regarding oral oncolytic adherence, safety and education, effective delivery of Survivorship Care Plans, effectiveness of tumor marker surveillance in early stage breast cancer, improving germline genetic testing rates in pancreatic cancer and, decreasing chemotherapy infusion wait times. He has made significant outreach to the community with several invitations to local and regional conferences educating local providers, cancer survivors and the general population. He serves on the Cancer Care Delivery Research Committee for both the NRG and Alliance cooperative groups and the Young Investigators Committee for NRG.
Disclosure
Financial relationships No, I have not had a financial relationship with an ineligible company within the past 24 months.
Tripti Chopade (MD)
null
Disclosure
Financial relationships No, I have not had a financial relationship with an ineligible company within the past 24 months.
- Hematologists
- Oncologists
- Surgeons
- Radiation Oncologists
- Oncology residents/fellows
- Oncology NPs/PAs
- Oncology pharmacists
- Oncology nurses
Target Audience
- Choose new therapeutic options for treating benign and malignant hematologic disorders & breast cancer.
- Review appropriate indications and contraindications to these therapeutic approaches.
- Integrate evolving diagnostic, prognostic, and therapeutic approaches to managing hematologic disorders and breast cancer patients.
- Individualize management of patients based on emerging data from clinical trials and evolving expert guidelines.
Learning Objectives
Upon successful completion of this educational activity, participants will be able to: